Michael Tees
Hematology & Oncology · Denver, CONPI 1407023385
Payments from drug & device makers
Across 653 payments — averaging $4173.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$912K
- Gilead$849K
- Beigene, Ltd.$272K
- Genmab U.S., Inc.$178K
- TG Therapeutics, Inc.$131K
- Regeneron$115K
- plus $270K from 27 others
Across 1 payment — averaging $1017.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 4 | $911,818 |
| Gilead | 248 | $848,678 |
| Beigene, Ltd. | 4 | $271,609 |
| Genmab U.S., Inc. | 43 | $177,759 |
| TG Therapeutics, Inc. | 136 | $131,178 |
| Regeneron | 17 | $114,528 |
| Merck | 2 | $68,228 |
| Genmab BV | 21 | $51,727 |
| Bristol Myers Squibb | 38 | $40,263 |
| Genentech, Inc. | 6 | $30,393 |
| Pharmacyclics LLC, An Abbvie Company | 44 | $27,395 |
| Institut DE Recherches Internationales Servier | 17 | $26,685 |
| Astrazeneca UK Limited | 6 | $17,236 |
| Johnson & Johnson | 12 | $3,496 |
| Organon | 1 | $1,235 |
| Daiichi Sankyo Inc. | 3 | $950 |
| AbbVie | 23 | $690 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $434 |
| Servier Bioinnovation | 1 | $375 |
| CSL Behring | 5 | $97 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Astellas Pharma US Inc | 2 | $41 |
| Taiho Oncology, Inc. | 2 | $35 |
| Novartis | 2 | $30 |
| Beigene USA, Inc. | 1 | $24 |
| Adaptive Biotechnologies Corporation | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Sanofi | 1 | $21 |
| Akcea Therapeutics, Inc. | 1 | $20 |
| Amgen | 1 | $17 |
| Incyte Corporation | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$2,725,109 in reported general payments places this provider in the 85th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Denver
- Allen CohnDenver$13.5M
- Robert RifkinDenver$11.3M
- Henning SchadeDenver$9M
- Jeffrey MatousDenver$8.4M
- Peter ForsbergDenver$5.5M
- Tara GregoryDenver$3.5M
- Mabel MardonesDenver$3M
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$1.8M
- Michael MarisDenver$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.